

61st

Business Report

From April 1, 2014 to March 31, 2015

Contents

To Our ShareholdersP.	.1
Summary of Our Business Operations (Consolidated)P.	3
Status of Research and DevelopmentP.	.5
Research and Development PipelineP.	6
Status of Production and Distribution /	
Outlook for Fiscal Year 2015P.	7
Special Offers to Our ShareholdersP.	8
TopicsP.	9
Financial Statements (Consolidated)P.1	1
Company InformationP.1	3
Share InformationP.1	4
Shareholder Memo	








We are pleased to report the results of fiscal year 2014 (61st business operations) for the period from April 1, 2014 to March 31, 2015.

Chairman and CEO Sachiaki Ibe President and COO Mitsuhiro Ibe



Overseas sales (🔲 : Left-hand scale) / Overseas sales to net sales ratio (🔶 : Right-hand scale)





During the fiscal year under review, the Japanese economy followed a path of moderate recovery. This mainly reflected improvement in the employment situation and growth in private capital investment resulting from proactive financial and fiscal management by the government. Nevertheless, there were many problems to be overcome, such as weak personal consumption following a consumption tax increase, and prospects for the economy continued to be unclear.

In the pharmaceuticals industry, the business environment remained difficult both in the ethical pharmaceuticals and the OTC drug fields. In the field of ethical pharmaceuticals, there was not only the implementation of drug price revisions in April last year but also further strengthening of efforts by the government to implement its policy to minimize medical expenses, such as the promotion of generic brand pharmaceuticals. In the OTC drug market, moreover, there continued to be a year-on-year decline in domestic demand and intensifying market competition.


Operating under such circumstances, the Zeria Group commenced the initial year of its three-year 8th Mid-Term Management Plan (from fiscal year 2014 to fiscal year 2016). In the fiscal year under review, the first year of this plan, the Group not only took its first step toward business development in Asia as a global company, but also worked to vigorously grow the Ethical Pharmaceuticals business and the Consumer Healthcare business, which have long been the two "wheels" of the Group. To achieve these goals, the Group actively channeled its business resources.

As a result of these activities, sales expanded in the Consumer Healthcare business due to growth in sales of the Hepalyse[®] product range. Nevertheless, net sales for the fiscal year under review were 61,012 million yen (down 1.6% from the previous fiscal year). This reflected struggling sales at the Ethical Pharmaceuticals business in Japan due to factors including the impact from the promotion of generic brand pharmaceuticals, and a delay in development of the market for Acofide[®], the therapeutic agent for functional dyspepsia, which was launched in June 2013. In terms of profits, operating income was 2,678 million yen (down 60.6%), ordinary income was 2,770 million yen (down 59.3%) and net income was 2,557 million yen (down 51.5%), due mainly to decreases in income from licenses and royalties and large increases in costs such as research and development expenses.


In fiscal year 2014, the overseas sales to net sales ratio was 17.2%, compared with 13.4% in the previous fiscal year.



Ethical Pharmaceuticals Business



Consolidated net sales in Ethical Pharmaceuticals Business




In the Ethical Pharmaceuticals business, in accordance with promotion codes, Zeria Pharmaceutical Co., Ltd. ("Zeria") sought to improve the quality of its medical representatives (MRs), and took steps to upgrade its medical information activities.

As for the mainstay product Asacol[®], a therapeutic agent for ulcerative colitis, although sales in Japan were impacted by a lull following a rush in demand ahead of the consumption tax increase, there was continued sales growth outside Japan through the strengthening of the sales structure of Tillotts Pharma AG. As a result, sales of this product were firm. Nevertheless, sales of other products including Acinon[®], an H₂ receptor antagonist, and Promac[®], a zinc-containing antiulcer agent, struggled due to the impact of drug price revisions in April last year and the promotion of generic brand pharmaceuticals. Furthermore, although Zeria is working in partnership with Astellas Pharma Inc. to guickly develop the market for Acofide®, the therapeutic agent for functional dyspepsia, achievement of this goal is progressing more slowly than planned.

As a result, net sales in the business amounted to 33,759 million yen (down 7.3% from the previous fiscal year).



Consumer Healthcare Business



In the Consumer Healthcare business, amidst the advancement of the super-aged society, Zeria worked to develop markets through the supply of self-medication products for the consumer.

The mainstay Hepalyse[®] product range posted sales growth as the result of further enhancement of product awareness through intensive advertising activities utilizing diverse forms of media such as TV advertisements. In particular, sales of the Hepalyse® W product range for sale in convenience stores, continued to show substantial sales growth following on from the previous fiscal year. In addition, Hepalyse® Amino (designated guasi-drug), which has been well received in Okinawa Prefecture since its launch in July 2014 there in advance of the rest of the country was put on sale nationwide in March 2015. In this way, Zeria also worked to enhance its lineup of products. Sales of the Chondroitin product range were firm as a result of sales activities that promoted its effectiveness. safety and high guality as a range of pharmaceuticals and clearly distinguished it from health foods. In addition, Zeria launched Prefemin® (a pharmacist intervention required OTC medicine), Japan's first European herbal direct OTC drug with an indication for premenstrual syndrome, in September last year. As a result, net sales in the business amounted to 27.095 million yen (up 6.7% from the previous fiscal year).



In the Research and Development division, Zeria is actively promoting overseas clinical trials of its own original drugs. At the same time, Zeria adopts in-licensed drugs that have gained global success and develops them for the Japanese market.

As part of Zeria's endeavors to build its pipeline of new drugs in its priority gastrointestinal field, Zeria is conducting a Phase III trial for Z-206 (Asacol®) for additional dosage and administration for ulcerative colitis in partnership with Kyowa Hakko Kirin Co., Ltd. Regarding its development in China, Zeria also submitted an application for approval in May 2013 following the completion of a Phase III trial.

For Zeria's own original drug Z-338 (Acofide[®]), it is conducting a Phase III trial targeting functional dyspepsia in Europe.

Zeria also commenced a Phase II trial for Z-215, a long lasting proton pump inhibitor in-licensed from Eisai Co., Ltd., targeting reflux esophagitis.

In addition, Zeria started a global Phase III joint clinical trial for Z-100 targeting cervical cancer in the Asian region including Japan.

For Z-360, Zeria is implementing a global Phase II joint clinical trial in the Asian region including Japan targeting pancreatic cancer.

Zeria started a Phase Ib trial for Z-213, a treatment for iron deficiency anemia in-licensed from Vifor (International) AG of Switzerland. Regarding Consumer Healthcare products, Zeria is developing over ten items, most notably European herbal medicines.

Meanwhile, Group company Tillotts Pharma AG is developing therapeutic drugs for lower gastrointestinal disease primarily in Europe.

Tillotts Pharma AG is conducting a Phase III trial in Europe and Canada for an improved mesalazine formulation benefiting from new technology targeting ulcerative colitis (Tillotts Pharma AG development code TP05).

In addition, Tillotts Pharma AG is conducting a Phase III trial in Europe and the USA for the therapeutic agent targeting familial adenomatous polyposis currently being co-developed with Cancer Prevention Pharmaceuticals, Inc. of the USA (Tillotts Pharma AG development code TP09).

As a result of these activities, research and development expenses for the fiscal year under review increased considerably from the results of the previous fiscal year to 9,882 million yen (up 32.4% from the previous fiscal year).

Status of Pipeline of New Drugs

I. Domestic 1) Gastrointestinal field

Stage	Development Code/ Generic Name	Development	Indications	Classification	Notes
		Ulcerative colitis Asacol [®] additional dosage and administration	pH-dependent controlled-release formulation	Original (Tillotts Pharma AG)	
Phase II	Phase II Z-360 Zeria		Pancreatic cancer	Gastrin CCK ² receptor antagonist	Original Asia Global Development
Phase II	Z-215	Zeria	Acid-related disorders	Long lasting proton pump inhibitor	In-licensed (Eisai)

2) Other fields

Stage	Development Code/ Generic Name	Development	Indications	Classification	Notes
Phase III	Z-100	Zeria	Cervical cancer	Immunomodulator	Original Asia Global Development
Phase Ib	Z-213/Ferric carboxymaltose	Zeria	Iron deficiency anemia	Intravenous iron replacement	In-licensed (Vifor (International) AG)

II. Overseas

Stage	Development Code/ Generic Name	Development	Indications	Classification	Notes
NDA filed (China)	Z-206/ Mesalazine	Co-development (Tillotts Pharma AG)	Ulcerative colitis Asacol®	pH-dependent controlled-release formulation	Original (Tillotts Pharma AG)
Phase III (Europe)	Z-338/ Acotiamide	le Zeria Functional dyspepsia		Upper gastrointestinal motility modulator	Original
Phase III (Asia)	Z-100	Zeria	Cervical cancer	Immunomodulator	Original
Phase II completed (North America)	Z-338/ Acotiamide	Zeria	Functional dyspepsia	Upper gastrointestinal motility modulator	Original
Phase II (Asia)	Z-360	Zeria	Pancreatic cancer	Gastrin CCK ² receptor antagonist	Original

III. Tillotts Pharma AG

which the body eliminates the drug.

Stage	Development Code/ Generic Name	Development	Indications	Classification	Notes
Phase III (Europe, Canada)	TP05/ Mesalazine	Tillotts Pharma AG	Ulcerative colitis	OPTICORE formulation	Original (Tillotts Pharma AG)
Phase III (Europe, USA)	TP09/CPP- 1X-Sulindac	Co-development (Tillotts Pharma AG - Cancer Prevention Pharmaceuticals, Inc.)	Familial adenomatous polyposis	Polyamine biosynthesis suppression	In-licensed (Cancer Prevention Pharmaceuticals, Inc.)

Reference					
helefellee	Phase I Clinical Trials		Phase II Clinical Trials	>	Phase III Clinical Trials
the efficad a small concentra	pletion of animal studies and confirmation of cy and safety, "drug candidates" are tested on group of healthy subjects. These trials te not only on safety, but also on how long it he body to absorb the drug and the degree to	clinic cand of u	r safety has been confirmed by Phase I al trials, the efficacy and safety of the "drug idate," as well as the appropriate method se such as dosage and administration ood, are tested on a small number of		By administering to a large number of patients, the final efficacy, safet and method of use of the "drug candidate" are studied. During thi phase, the "drug candidate" is tested against other drugs on the marke or against placebo*. In many cases, stringent testing methods called double-blind trials are performed.

* Placebo: A fake drug that does not contain the active ingredient, but which is indistinguishable from the "drug candidate" by outer appearance or taste.

patients against placebo*.

(As of May 8, 2015)

Status of Production and Distribution

In Zeria's Production and Distribution division, it attached top priority to securing the highest-possible quality. In Zeria's Production related departments, operations concentrated on the main theme of reducing costs while securing even higher quality. Meanwhile, in the Distribution related departments, Zeria outsourced distribution operations as part of an overall goal to boost increases in operational efficiency and cost reductions.

Looking ahead, demand for OTC drugs is expected to continue expanding; to ensure stable supplies of such drugs, as well as Zeria's other products, Zeria started renovation work at its Saitama Plant to secure the necessary production capacity.

Close-up shot

Hepalyse® Amino Launched across Japan

On March 23, 2015, Zeria commenced sales of Hepalyse[®] Amino (designated quasi-drug) in convenience stores across Japan. Already on sale in Okinawa Prefecture in advance of the rest of the country, the product is a mini drink of the Hepalyse[®] brand nutrients available in convenience stores and tonics for physical fatigue and exhaustion.



Hepalyse[®] Amino is a drink for people suffering from tiredness that contains five amino acids including branched chain amino acids (BCAAs), which provide a source of energy for active muscles. The drink combines these with other ingredients that aid recovery from fatigue, including taurine, and vitamins B₂ and B₆. Zeria will be rolling this product out actively as part of its Hepalyse[®] brand lineup.

Outlook for Fiscal Year 2015

For the consolidated outlook for fiscal year 2015 ending March 31, 2016, Zeria forecasts that it will secure increases in both sales and profits, with net sales of 65.0 billion yen (up 6.5% from the previous fiscal year), operating income of 4.0 billion yen (up 49.3%), ordinary income of 3.5 billion yen (up 26.3%), and net income of 3.0 billion yen (up 17.3%).

Net sales

In the Ethical Pharmaceuticals business, Zeria expects an increase in sales resulting from increased sales of Asacol®, the mainstay therapeutic agent for ulcerative colitis, in Japan and overseas, and further development of the market for the therapeutic agent Acofide® for functional dyspepsia, although Zeria expects continued powerful promotion of generic brand pharmaceuticals. In the Consumer Healthcare business, Zeria expects continued increases in sales from sales expansion for mainstay product ranges such as the Hepalyse® product range and the Chondroitin product range, following on from the previous year.

Income

Zeria forecasts higher operating income, ordinary income and net income compared with the fiscal year under review on the back of increased sales of mainstay products, despite its expectations that research and development expenses will continue to be high for reasons including a development theme introduced in the previous fiscal year and progress in clinical trials being conducted overseas.

	61st Term	62nd Term (Forecast)
Net Sales	¥61,012 million (down 1.6% (from the previous fiscal year)	¥65,000 million (up 6.5% (from the previous fiscal year)
Operating Income	¥2,678 million (down 60.6% (from the previous fiscal year)	¥4,000 million (up 49.3% (from the previous fiscal year)
Ordinary Income	¥2,770 million (down 59.3% (from the previous fiscal year)	¥3,500 million (up 26.3% (from the previous fiscal year)
Net Income	¥2,557 million (down 51.5% (from the previous fiscal year)	¥3,000 million (up 17.3% (from the previous fiscal year)



Special Offers to Our Shareholders



Zeria offers a hospitality program to its shareholders in recognition of their constant support. Shareholders who own 1,000 or more of Zeria's shares can choose from one of the five options A to E. Shareholders who own 100 or more but less than 1,000 of Zeria's shares receive option F. Zeria hopes its shareholders will try the gift products for better understanding of its wide-ranging product structure.



Soft drinks, Designated quasi-drug, Food for specified health uses Set of aluminum can drinks and Hepalyse® W





Health drink 2 bottles of Chondrobe[®] Concentrate, JUNKOU[®]





Cosmetics and health products Set of ChondroMax[®] and Aposty[®]





Chondroitin-Content Intensive Nighttime Essence 2 bottles of ZZ:CC[®] ADSORB ESSENCE (30g)





Drink containing liver extract and turmeric extract 10 bottles of Hepalyse[®] W





Acquisition of Shares in F. T. Pharma of Vietnam

On April 17, 2015, Zeria concluded a contract to acquire 49.0% of shares issued by the Vietnamese pharmaceutical manufacturing and sales company Pharmaceutical Joint Stock Company of February 3rd (location: Ho Chi Minh, Vietnam; representative: Le Thanh Su; hereinafter "F. T. Pharma").

Zeria has so far developed its business overseas by acquiring Tillotts Pharma AG of Switzerland in September 2009 and ZPD A/S of Denmark in September 2010. Under its three-year 8th Mid-Term Management Plan launched in fiscal year 2014, Zeria is going to strengthen its foundation as a global company with business development in the rapidly growing Asian region, following its expansion in Europe.

F. T. Pharma, of which Zeria is now acquiring shares, is a medium-sized pharmaceutical manufacturing and sales company that makes and sells ethical pharmaceuticals, OTC drugs, and health foods in Vietnam. F. T. Pharma has a pharmaceutical manufacturing plant that conforms to WHO-GMP and it produces and sells a combined total of approximately 200 ethical pharmaceuticals and OTC drugs. After acquiring the shares, Zeria is considering selling items suited to Vietnamese needs from among the Zeria Group's extensive lineup of products including ethical pharmaceuticals, OTC drugs, cosmetics and supplements using F. T. Pharma as a base, while maintaining and developing F. T. Pharma's existing operations.

Acquisition of the shares in F. T. Pharma will enable Zeria to use the company as a base for the Group's business development in the Asian region and Zeria will step up its efforts to strengthen its foundation as a global company.

F. T. Pharma Company Outline

Name	Pharmaceutical Joint Stock Company of February 3rd
A d d r e s s	10 Cong Truong Quoc Te, District 3, Ho Chi Minh City, Vietnam
Representative	Le Thanh Su (Chairman of the Board of Directors)
Business Activities	Manufacturing and sales of pharmaceuticals, manufacturing and sales of health foods, etc.
Paid-in Capital	VND 46,500 million (¥0.26 billion)
Number of Employees	331 (as of September 30, 2014)

(Note) Vietnamese dong (VND) are converted to yen using the average exchange rate between March 16, 2015 and April 15, 2015, of VND 1 = ¥0.00557.



Launch of Hepalyse[®] W Sparkling, a New Carbonated Drink Sold in Convenience Stores

On June 29, 2015, Zeria will start selling Hepalyse[®] W Sparkling in convenience stores across Japan as a new carbonated drink product in the Hepalyse[®] W (Double) series.

Based on the ingredients in Hepalyse[®] W drinks, which contain both liver extract and turmeric extract, Hepalyse[®] W Sparkling is carbonated for a refreshed feeling and contains natural caffeine to sharpen the mind, boosting energy from the morning on.

Zeria markets a number of products for sale in convenience stores, and these products have become extremely popular: Hepalyse[®] W and Hepalyse[®] W Hyper (soft drinks), Hepalyse[®] Amino (designated quasi-drug drink), and Hepalyse[®] W Pastille Type (dietary supplement). The addition of Hepalyse[®] W Sparkling to this lineup will enable consumers to choose the product best suited to the situation as well as their personal preferences.

Characteristics of Hepalyse® W Sparkling

- Carbonated for a refreshed feeling and containing natural caffeine to sharpen the mind: A morning boost for those with a busy social life.
- A burst of pineapple flavor: Just the right amount of carbonation for a pineapple taste that refreshes and tastes good.
- Appealing ingredients: Contains black pepper extract, which enhances absorption of turmeric extract (curcumin), and vitamins.

To coincide with the launch, a television advertisement for Hepalyse[®] W Sparkling will start airing throughout Japan from early July. The advertisement featured the actor and sports commentator Jay Kabira, who had appeared in previous advertisements for the same range.





Consolidated Balance Sheets (Summary)

(Unit: ¥million*							
Term	Previous Fiscal Year	Current Fiscal Year	Term	Previous Fiscal Year	Current Fiscal Year		
Item	(As of March 31, 2014)	(As of March 31, 2015)	Item	(As of March 31, 2014)	(As of March 31, 2015)		
Assets			Liabilities				
Current Assets	49,902	45,680	Current Liabilities	25,953	21,911		
Cash and Deposits	22,202	18,012	Notes and Accounts Payable-Trade	3,718	2,383		
Notes and Accounts Receivable-Trade	15,484	16,241	Short-Term Loans Payable	12,593	11,572		
Inventories	7,733	8,189	Other	9,641	7,954		
Deferred Tax Assets	1,368	943	Noncurrent Liabilities	14,806	11,786		
Other	3,122	2,312	Long-Term Loans Payable	13,867	10,636		
Allowance for Doubtful Accounts	(10)	(18)	Net Defined Benefit Liability	154	371		
Noncurrent Assets	49,591	50,587	Asset Retirement Obligations	73	74		
Property, Plant and Equipment	21,952	22,021	Other	710	705		
Buildings and Structures	7,340	7,092	Total Liabilities	40,759	33,697		
Machinery, Equipment and Vehicles	2,505	2,008	Net Assets				
Land	11,578	11,579	Shareholders' Equity	54,025	55,697		
Construction in Progress	10	940	Capital Stock	6,593	6,593		
Other	517	401	Capital Surplus	12,716	12,716		
Intangible Assets	13,250	12,344	Retained Earnings	34,717	36,392		
Investments and Other Assets	14,387	16,221	Treasury Stock	(2)	(3)		
Investment Securities	10,544	9,731	Accumulated Other Comprehensive Income	4,709	6,872		
Deferred Tax Assets	738	85	Valuation Difference on Available- for-Sale Securities	1,307	1,474		
Net Defined Benefit Asset	2,023	5,400	Foreign Currency Translation Adjustment	3,533	3,994		
Other	1,129	1,049	Remeasurements of Defined Benefit Plans	(130)	1,403		
Allowance for Doubtful Accounts	(47)	(44)	Total Net Assets	58,734	62,570		
Total Assets	99,493	96,268	Total Liabilities and Net Assets	99,493	96,268		

Unit: ¥million rounded down to nearest million

(Unit: ¥million*)

		/

Consolidated Statements of Income (Summary) (Unit: ¥million*)

Term	Previous Fiscal Year	Current Fiscal Year
Item	(From April 1, 2013	(From April 1, 2014
	to March 31, 2014)	to March 31, 2015)
Net Sales	61,996	61,012
Cost of Sales	18,347	18,521
Gross Profit	43,649	42,491
Reversal of Provision for Sales Returns	105	110
Provision for Sales Returns	110	62
Gross Profit-Net	43,644	42,539
Selling, General and Administrative Expenses	36,854	39,861
Operating Income	6,790	2,678
Non-Operating Income	332	338
Non-Operating Expenses	318	246
Ordinary Income	6,803	2,770
Extraordinary Income	608	1,507
Extraordinary Loss	102	457
Income before Income Taxes	7,309	3,819
Income Taxes-Current	2,562	1,315
Income Taxes-Deferred	(527)	(53)
Income before Minority Interests	5,274	2,557
Minority Interests in Loss	(2)	-
Net Income	5,277	2,557

Consolidated Statements of Cash Flows (Summary) (Unit: ¥million					
Previous Fiscal Year (From April 1, 2013 to March 31, 2014)	Current Fiscal Year (From April 1, 2014 to March 31, 2015)				
6,573	653				
(2,013)	475				
9,001	(5,839)				
1,274	177				
14,835	(4,533)				
7,235	22,070				
-	343				
22,070	17,880				
	Previous Fiscal Year (from April 1, 2013) to March 31, 2014) (2,013) 9,001 1,274 14,835 7,235				

Unit: ¥million rounded down to nearest million


(Unit: ¥million*)

Unit: ¥million rounded down to nearest million

Consolidated Statements of Changes in Net Assets (Summary) (From April 1, 2014 to March 31, 2015)

Shareholders' Equity Accumulated Other Comprehensive Income Foreign Currency Translation Capital Stock Adiustmen[.] 6,593 4,709 Balance at the Beginning of Current Period 12,716 34,717 (2) 54,025 1,307 3,533 (130)58,734 Cumulative Effects of Changes 480 480 480 in Accounting Policies Balance at the Beginning of Current Period 6,593 12,716 35,198 (2) 54,505 1,307 3,533 (130)4,709 59,215 Reflecting Changes in Accounting Policies Changes of Items during the Period Change of Scope of Consolidation 229 229 229 Dividends from Surplus (1, 593)(1, 593)(1, 593)Net Income 2,557 2,557 2,557 Purchase of Treasury Stock (1) (1) (1) Net Changes of Items Other 166 461 1,534 2,162 2,162 than Shareholders' Equity Total Changes of Items during the Period 1,193 (1) 1,192 166 461 1,534 2,162 3,354 36,392 55,697 Balance at the End of Current Period 6,593 12,716 (3) 1,474 3,994 1,403 6,872 62,570

Unit: ¥million rounded down to nearest million



Established:	December 1955
Paid-in Capital:	¥6,593,398,500
Number of Employees:	1,426 (Consolidated)
Business Activities:	1. Manufacturing, sales, import and export of pharmaceuticals, quasi-drugs and reagents.
	2. Manufacturing, sales, import and export of cosmetics, health foods, soft drinks, hygienic goods and medical devices.

Directors and Audit & Supervisory Board Members (As of June 26, 2015)

Chairman and CEO	Sachiaki Ibe
President and COO	Mitsuhiro Ibe
Executive Vice President	Hirokazu Endo
Senior Managing Director	Shigeya Furuhata
Managing Director	Makoto Kishimoto
Director	Akira Ohno
Director	Tetsuo Komori
Director	Yasuhiro Hayashi
Director	Masahiro Fukahori
Director	Hiroki Kato
Director	Yoshihiro Hiraga
Director	Katsuyuki Ishii
Director	Hidekazu Yokote
Director	Toshiaki Kawagoe
Audit & Supervisory Board Member	Masahiko Hanada
Audit & Supervisory Board Member	Koujirou Takami
Audit & Supervisory Board Member (Outside)	Yukiko Naka
Audit & Supervisory Board Member (Outside)	Hiroshi Wakabayashi

Place of Business

- Headquarters
- Sapporo Branch
- Sendai Branch
- Tokyo Branch
- Tokyo 3rd Sales Office
- Kanagawa 1st and 2nd Sales Office
- Saitama Sales Office
- Chiba Sales Office
- Kita Kanto Sales Office
- Koshinetsu Sales Office
- Nagoya Branch
- Shizuoka Sales Office
- Osaka Branch
- Osaka 2nd Sales Office
- Kobe Sales Office

- Keiji Sales Office
- Hokuriku Sales Office
- Chugoku & Shikoku Branch
- Okayama Sales Office
- Takamatsu Sales Office
- Fukuoka Branch
- Central Research Laboratories
- Saitama Plant
- Tsukuba Plant
- Tokyo Distribution Center
- Sapporo Distribution Center
- Saitama Distribution Center
- Osaka Distribution Center
- Kyushu Distribution Center

 Other Sales Office Aomori, Utsunomiya, Kanetsu, Yamaguchi, Yonago, Matsuyama, Kochi, Nagasaki, Kumamoto, Oita, Kagoshima, Okinawa

Number of Consolidated Subsidiaries: 11

- Tillotts Pharma AG (Switzerland)
- Zeria Healthway Co., Ltd.
- ZPD A/S (Denmark)
- IONA INTERNATIONAL CORPORATION
- Zevice Co., Ltd.
- Tillotts Pharma AB (Sweden)
- Tillotts Pharma Ltd. (Ireland)
- Tillotts Pharma UK Ltd. (United Kingdom)
- Tillotts Pharma Czech s.r.o. (Czech Republic)
- Tillotts Pharma Spain S.L.U. (Spain)
- Tillotts Pharma GmbH (Germany)




Status of Shares

(i) Number of authorized shares:	119,860,000 shares
(ii) Number of shares outstanding:	53,119,190 shares
(iii) Number of shareholders:	10,867

Major Shareholders


Name of Shareholder	Number of Shares Held	Percentage Held (%)
Ibe Corporation	4,741,847	8.9
Japan Trustee Service Bank, Ltd. (Trust Account)	2,626,800	4.9
The Bank of Tokyo-Mitsubishi UFJ, Ltd.	2,107,050	4.0
Morinaga Milk Industry Co., Ltd.	2,040,215	3.8
Sachiaki Ibe	1,592,967	3.0
Zeria Pharmaceutical Co., Ltd. Employee Stockholding Plan	1,508,704	2.8
Sumitomo Mitsui Banking Corporation	1,406,131	2.6
Mizuho Bank, Ltd.	1,406,053	2.6
The Master Trust Bank of Japan, Ltd. (Trust Account)	1,237,700	2.3
Resona Bank, Limited	1,182,385	2.2

Distribution of Shares by Shareholder Type



(Note) The percentage held is calculated by subtracting treasury stock (totaling 3,355 shares).

Share Price and Trading Volume



Shareholder Memo

Fiscal Year	From April 1 of each year to March 31 of the following year	
Ordinary General Meeting of Shareholders	Late June of each year	 Applications for change of address or for purchase demands of fractional shares, etc. Please send such notifications or applications to the securities company where your account is held.
Record Date	Ordinary General Meeting of Shareholders and end of term dividend: March 31 of each year Interim dividend: September 30 of each year	For shareholders for whom a special account has been opened because there is no account held by a securities company, please send such notifications or applications to Sumitomo Mitsui Trust Bank, Limited, the account management institution for the special account.
Transfer Agent	Sumitomo Mitsui Trust Bank, Limited 1-4-1 Marunouchi, Chiyoda-ku, Tokyo	 Applications for payment of dividends payable Please send such applications to the transfer agent, Sumitomo Mitsui Trust Bank, Limited.
Account Management Institution for Special Account	Sumitomo Mitsui Trust Bank, Limited 1-4-1 Marunouchi, Chiyoda-ku, Tokyo	 Statement of Dividend Calculation The "Statement of Dividend Calculation" that is sent to shareholders at the time of dividends payment serves as your "Payment Notification Statement," based on the provisions of the Act
Mailing Address	Stock Transfer Agency Business Planning Department, Sumitomo Mitsui Trust Bank, Limited 2-8-4 Izumi, Suginami-ku, Tokyo 168-0063	on Special Measures Concerning Taxation. When you file your final tax return, you can use this document as the accompanying documentation. Shareholders who receive payment of dividends by the dividend warrant shall also receive the "Statement of Dividend Calculation." Shareholders who file final tax returns should store this
(Inquiry information)	TEL: 0120-782-031 (toll-free) Handling operation is conducted in main branch and all domestic branches of Sumitomo Mitsui Trust Bank, Limited.	document in a secure place.



The latest IR information may be viewed on the Company's website.

The Company has set up a website for the purpose of providing accurate information on a timely basis. The website contains a broad array of information useful for shareholders and investors, from IR information to the latest news.

http://www.zeria.co.jp/english/



Customer Service, Zeria Pharmaceutical Co., Ltd.

10-11 Nihonbashi-kobunacho, Chuo-ku, Tokyo 103-8351 TEL 03-3663-2351 (Main) FAX 03-3663-2352 03-3661-2080 http://www.zeria.co.jp/

